

大崎往夫	Ⅲ. 肝癌治療実践のKnack&Pitfalls 2.RFA(2)RFA のpractice (d)バイポーラ電極.	診療ガイドラインに沿った肝癌治療の要点と盲点		P277-287	2013
Osaki Y, Ikeda K, Izumi N, Yamashita S, Kumada H, Hatta S, Okita K.	Clinical Characteristics of Patients who Developed Hepatocellular Carcinoma after Hepatitis C Virus Eradication with Interferon Therapy: Current Status in Japan.	INTERNAL MEDICINE.	52	2701-2706	2013
Osaki Y, Ikeda K, Izumi N, Yamashita S, Kumada H, Hatta S, Okita K	Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers.	Journal of Gastroenterology	48	874-883	2013
Nishikawa H, Osaki Y	Clinical significance of occult hepatitis B infection in progression of liver disease and carcinogenesis.	J Cancer	4	473-480	2013
Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y.	Comparison of clinical characteristics and survival after surgery in patients with non-B and non-C hepatocellular carcinoma and hepatitis virus-related hepatocellular carcinoma.	J Cancer	4	502-513	2013
Nishikawa H, Osaki Y	Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma.	Hepatol Res.	Jul 2		2013
Nishikawa H, Osaki Y, Kita R, Kimura T, Ohara Y, Takeda H, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H, Nishiguchi S.	Comparison of arterial chemoembolization transcatheter and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma	Oncology Reports	31	65-72	2014

喜多竜一,大崎往夫	CTPA/CTHA	動画で身につく 肝疾患の基本手技—インターベシヨン治療の秘訣.		53-60	
西川浩樹, 崎往夫	Current issue 「TACEをRFAに先行させるべきか?」	診療ガイドラインに沿った肝癌治療の要点と盲点		307-309	2013
Osaki Y, Ueda Y, Marusawa H, Nakajima J, Kimura T, Kita R, Nishikawa H, Saito S, Henmi S, Sakamoto A, Eso Y, Chiba T	Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study.	Journal of Gastroenterology.	47	444-51	2013
Nishikawa H,Osaki Y, Takeda H, Sakamoto A,Saito S,Nishijima N, Nasu A, ,Arimoto A, Kita R, Kimura T.	Effect of body mass index on survival after curative therapy for non-B-C hepatocellular carcinoma.	Journal of Gastrointestinal and Liver Diseases.	22	173-181	2013
Nishikawa H, Nshijima N, Arimoto A, Inuzuka T, Kita R, Kimura T,Osaki Y	Effect of nucleoside analog use in patients with hepatitis B virus-related hepatocellular carcinoma.	Hepatol Res.	May 24,		2013
Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y.	Effect of transcatheter arterial chemoembolization prior to surgical resection for hepatocellular carcinoma..	International Journal of Oncology	42	151-160	2013
Takeda H, Nishikawa H, Iguchi E,Ohara Y, Sakamoto A, Saito S,Nishijima N, Nasu A,Komekado H, Kita R, Kimura T,Osaki Y	Effect of treatment with branched-chain amino acids during sorafenib therapy for unresectable hepatocellular	Hepatol Res.	Apr 2		2013

Inoue T,Hyodo T Murakami T,Takayama Y Nishie A,Higaki A, Korenaga K Sakamoto A,Osaki Y Akita H, Chayama K, Suda T,Takano T Miyoshi K,Koda M Numata K,Tanaka H Iijima H,Ochi H, Hirooka M Imai Y,Kudo M	Hypovascular Hepatic Nodules Showing Hypointense on the Hepatobiliary-Phase Image of Gd-EOB-DTPA-Enhanced MRI to Develop a Hypervascular Hepatocellular Carcinoma: A Nationwide Retrospective Study on Their Natural Course and Risk Factors.	Digestive Disease.	31	472-479	2013
Kudo M,Osaki Y Matsunaga T Kasugai H,Oka H Seki T	Hepatocellular carcinoma in child-pugh C cirrhosis: prognostic factors and survival benefit of nontransplant treatments	Digestive Disease	31	490-498	2013
Satoru H Masatoshi K, Yukio O, Hiroo MTadashi I, Akihiro M, Eiji T Toshiharu S, Kazuomi U, Tatsuo I, Norihisa Y, Naoshi N	Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B	Journal of Medical Virology.	85	987-995	2013
Nishikawa H Arimoto A Wakasa T,Kita R Kimura T,Osaki Y	Lack of correlation between the antibody to hepatitis B core antigen and survival after surgical resection for hepatitis C virus-related hepatocellular carcinoma	Oncol Rep	30	91-98	2013
Nishikawa H, Osaki Y	Non-B,non-C hepatocellular carcinoma (Review).	Int J Oncol.	43	1333-1342	2013
Nishikawa H, Arimoto A,Wakasa T Kita R,Kimura T Osaki Y.	Pre-treatment C-reactive protein as a prognostic factor for recurrence after surgical resection of hepatocellular carcinoma.	Anticancer Research	33	1181-1188	2013
Nishikawa H Kimura T,Kita R Osaki Y	Radiofrequency ablation for hepatocellular carcinoma	Int J Hyperthermia.	29	558-568	2013

Nishikawa H, Osaki Y,Iguchi E Takeda H,Matsuda F Nakajima J, Sakamoto A, Hatamaru K, Saito S,Nasu A Kita R,Kimura T	Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes.	Journal of Gastroenterology	48	951-965	2013
Nishikawa H Osaki Y,Arimoto A Kita R,Kimura T.	Relation between antibody to hepatitis B core antigen and survival after curative therapy for non-B non-C hepatocellular carcinoma	Anticancer Research	33	2211-2219	2013
Nishiguchi S, Enomoto H Aizawa N Nishikawa H, Osaki Y,Tsuda Y, Higuchi K,Okazaki K, Seki T,Kim SR Hongo Y,Jyomura H Nishida N,Kudo M	Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial. ReGIT-J study.	J Gastroenterol	Mar 30		2013
大崎往夫.	RFAで腫瘍を大きく丸く焼却する工夫にはどんなものがありますか？	肝 癌 診 療 Q&A			
大崎往夫	RVSの進化とその有用性	INNERVISION.	28	100-101	2013
Nishikawa H Arimoto A Wakasa T Kita R,Kimura T Osaki Y	Surgical resection for hepatocellular carcinoma: clinical outcomes and safety in elderly patients.	Eur J Gastroenterol Hepatol.	25	912-919,	2013
Nishikawa H Osaki Y Iguchi E Koshikawa Y,Ako S ,Inuzuka T,Takeda H, Nakajima J, Matsuda F, Sakamoto A Henmi S,Hatamaru K Ishikawa T,Saito S Nasu A,Kita R, Kimura T	The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation	J Clin Gastroenterol	14	359-366	2013
Nishikawa H Arimoto A,Wakasa T, Kita R, Kimura T,Osaki Y	The Relation between Obesity and Survival after Surgical Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma.	Gastroenterol Res Pract.		430-438	2013

Nishikawa H Kimura T,Kita R Osaki Y	Treatment for Hepatocellular Carcinoma in Elderly Patients: A Literature Review.	J Cancer.	4	635-643	2013
木村 達, 坂本 梓 大崎往夫	ボリュームデータを利用した超音波診断と治療ナビゲーション—肝癌診療への応用と課題—	超 音 波 TECHNO	5-6	79-87,	2013
大崎往夫	肝癌の治療 肝癌に対するラジオ波凝固療法	月刊 臨牀と 研究	90	79-85	2013
西川浩樹	肝細胞癌患者におけるラジオ波焼灼療法後の分岐鎖アミノ酸顆粒製剤長期投与の影響.	FOCUS on BCAA			
大崎往夫	肝臓病の最新治療	肝友だより		33-40	2013
竹田浩彦, 喜多竜一 金坂 卓, 中島 潤 松田史博, 坂本 梓 幡丸景一, 齊藤澄夫 那須章洋, 西川浩樹 米門秀行, 関川 昭津 村剛彦, 圓尾隆典岡部 純弘, 木村 達大崎往 夫, 若狭朋子 中島 収	肝転移巣の自然破裂により腹腔内出血をきたした胃原発hepatoid adenocarcinoma の1剖検例.	日本消化器病 学会雑誌	110	1625-1632	2013
竹田治彦,大崎往夫 大原芳章, 坂本 梓 齋藤澄夫, 西島規浩 那須章洋, 西川浩樹 米門秀行, 喜多竜一 木村 達	切除不能進行肝癌に対するsorafenib療法の初期投与量に関する検討—減量投与の意義と問題について	肝臓.	54	169-177	2013
木村 達, 大崎往夫	第II部 Sonazoid による造影超音波 第3章 Sonazoid 超音波の基礎知識 4.最適な検査条件 4.HITACHI	EOB-MRI/Sonazoid 超音波による 肝癌の診断と 治療		235-240	

#### IV. 研究成果の刊行物・別刷

# $\alpha$ -Fetoprotein Levels After Interferon Therapy and Risk of Hepatocarcinogenesis in Chronic Hepatitis C

Yasuhiro Asahina,<sup>1,3</sup> Kaoru Tsuchiya,<sup>1</sup> Takashi Nishimura,<sup>1,4</sup> Masaru Muraoka,<sup>1,5</sup> Yuichiro Suzuki,<sup>1,5</sup> Nobuharu Tamaki,<sup>1</sup> Yutaka Yasui,<sup>1</sup> Takanori Hosokawa,<sup>1</sup> Ken Ueda,<sup>1</sup> Hiroyuki Nakanishi,<sup>1</sup> Jun Itakura,<sup>1</sup> Yuka Takahashi,<sup>1</sup> Masayuki Kurosaki,<sup>1</sup> Nobuyuki Enomoto,<sup>5</sup> Mina Nakagawa,<sup>2</sup> Sei Kakinuma,<sup>2,3</sup> Mamoru Watanabe,<sup>2</sup> and Namiki Izumi<sup>1</sup>

The effects of interferon (IFN) treatment and the post-IFN treatment  $\alpha$ -fetoprotein (AFP) levels on risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C (CHC) are unknown. To determine the relationship between AFP and alanine transaminase (ALT) levels and HCC risk, a cohort consisting of 1,818 patients histologically proven to have CHC treated with IFN were studied. Cumulative incidence and HCC risk were analyzed over a mean follow-up period of 6.1 years using the Kaplan-Meier method and Cox proportional hazard analysis. HCC developed in 179 study subjects. According to multivariate analysis, older age, male gender, advanced fibrosis, severe steatosis, lower serum albumin levels, nonsustained virological response (non-SVR), and higher post-IFN treatment ALT or AFP levels were identified as independent factors significantly associated with HCC development. Cutoff values for ALT and AFP for prediction of future HCC were determined as 40 IU/L and 6.0 ng/mL, respectively, and negative predictive values of these cutoffs were high at 0.960 in each value. The cumulative incidence of HCC was significantly lower in patients whose post-IFN treatment ALT and AFP levels were suppressed to less than the cutoff values even in non-SVR patients. This suppressive effect was also found in patients whose post-IFN treatment ALT and AFP levels were reduced to less than the cutoff values despite abnormal pretreatment levels. **Conclusion:** Post-IFN treatment ALT and AFP levels are significantly associated with hepatocarcinogenesis. Measurement of these values is useful for predicting future HCC risk after IFN treatment. Suppression of these values after IFN therapy reduces HCC risk even in patients without HCV eradication. (HEPATOLOGY 2013;58:1253-1262)

Hepatocellular carcinoma (HCC), one of the most frequent primary liver cancers,<sup>1,2</sup> is the third most common cause of cancer mortality worldwide.<sup>3</sup> Hepatitis C virus (HCV) infection is a common cause of chronic hepatitis, which progresses to HCC in many patients.<sup>4</sup> In the last two decades, interferon (IFN) therapy has been used to treat chronic hepatitis C (CHC) with the goal of altering

the natural history of this disease. Although HCV eradication with IFN therapy for CHC has been shown to prevent HCC,<sup>5-9</sup> HCC sometimes develops even after achieving viral eradication.<sup>5</sup> Because the number of sustained virological responders (SVRs) is increasing along with recent advances in the development of effective anti-HCV therapy, it is very important to determine factors responsible for HCC

Abbreviations: AFP,  $\alpha$ -fetoprotein; ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet ratio index; CHC, chronic hepatitis C; CT computed tomography;  $\gamma$ -GTP, gamma-glutamyl transpeptidase; HCC, hepatocellular carcinoma; HCV, Hepatitis C virus; IFN, interferon; MRI, magnetic resonance imaging; PEG-, pegylated; RBV, ribavirin; ROC, receiver operator characteristic; SVR, sustained virological response.

From the <sup>1</sup>Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan; <sup>2</sup>Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan; <sup>3</sup>Department of Liver Disease Control, Tokyo Medical and Dental University, Tokyo, Japan; <sup>4</sup>Department of Gastroenterology, Faculty of Medicine, Shiga University of Medical Science, Shiga, Japan; <sup>5</sup>First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.

Received February 19, 2013; accepted April 4, 2013.

Supported by grants from the Japanese Ministry of Education, Culture, Sports, Science, and Technology, and the Japanese Ministry of Welfare, Health, and Labor.

development among IFN-treated patients. However, this information is difficult to determine because of the paucity of large-scale, long-term cohort studies.

The 70-kDa glycoprotein  $\alpha$ -fetoprotein (AFP), encoded by a gene located on chromosome 4, is the major serum protein during fetal life.<sup>10</sup> Shortly before birth, AFP is replaced by albumin as the major serum protein,<sup>11,12</sup> and thereafter, serum AFP levels remain extremely low throughout life (<10 ng/mL). Because serum AFP levels are frequently elevated in patients with HCC and germ-cell tumors, measurement of AFP is widely used as a serological marker for these tumors.<sup>8,13</sup> However, AFP levels are sometimes elevated in patients with chronic viral hepatitis and cirrhosis who do not have HCC.<sup>3,19</sup> While one possible explanation for this elevation is liver inflammation, in patients with CHC, the relationship between AFP and markers of liver inflammation such as alanine aminotransferase (ALT) is unclear. Moreover, although several reports suggest that pre-IFN treatment ALT and AFP levels in patients or those in patients who did not undergo subsequent treatment are associated with the development of HCC, it is unclear whether post-IFN treatment ALT and AFP levels are associated with hepatocarcinogenesis in patients with CHC. Hence, to clarify these associations we conducted a large-scale, long-term cohort study of patients with CHC to analyze the influence of ALT and AFP levels before and after IFN therapy on hepatocarcinogenesis in addition to other host and virological factors.

## Patients and Methods

**Patients.** Patients chronically infected with HCV who had histologically proven chronic hepatitis or cirrhosis and had undergone IFN treatment between 1992 and 2010 were enrolled in the cohort. HCC was definitively ruled out by ultrasonography, dynamic computed tomography (CT), and/or magnetic resonance imaging (MRI) on enrollment. Patients were excluded if they had a history of HCC at the time of liver biopsy, autoimmune hepatitis, primary biliary cirrhosis, excessive alcohol consumption ( $\geq 50$  g/day), hepatitis B surface antigen, or antihuman immunodeficiency virus antibody.

Based on these criteria, a total of 2,689 patients were initially enrolled. Of these, 223 (8.3%) patients were excluded from the cohort because of loss to follow-up. In the remaining 2,466 patients, 133 and 515 patients were excluded from this analysis because of short follow-up and retreatment with IFN-based therapy during the follow-up period, respectively. Thus, the cohort comprising 1,818 patients was analyzed in the present study. Written informed consent was obtained from all patients and the Ethical Committee of Musashino Red Cross Hospital approved this study, which was conducted in accordance with the Declaration of Helsinki.

**Histological Evaluation.** To obtain liver specimens, laparoscopic or ultrasound-guided liver biopsies were performed with 13G or 15G needles, respectively. The median length of specimen was 18 mm (range, 11-41 mm), and the mean number of portal tracts was 17 (range, 9-35). The stage of fibrosis and the grade of inflammatory activity were scored by two pathologists according to the classification of Desmet et al.<sup>24</sup> The percentage of steatosis was quantified by determining the average proportion of hepatocytes affected.

**IFN Therapy and Definitions of Response to IFN Therapy.** All patients had chronic HCV infection at liver biopsy, which was confirmed by the presence of HCV-RNA in serum. All IFN therapies were initiated within 48 weeks after liver biopsy. Among the 1,818 patients, 535 received IFN $\alpha$  or IFN $\beta$  monotherapy for 24 weeks, 244 patients received IFN $\alpha$  ribavirin (RBV) combination therapy for 24 weeks, 299 patients received pegylated (PEG-) IFN $\alpha$  monotherapy for 48 weeks, and 760 patients received PEG-IFN $\alpha$  RBV combination therapy for 48-72 weeks.

Patients negative for serum HCV-RNA 24 weeks after IFN therapy completion were defined as SVRs. Patients who remained positive for HCV-RNA 24 weeks after therapy completion were defined as non-SVRs. HCV-RNA was determined by the qualitative Amplicor or TaqMan HCV assay (Roche Molecular Diagnostics, Tokyo, Japan).

**Data Collection and Patient Follow-up.** At enrollment, patient characteristics, biochemical,

Address reprint requests to: Yasuhiro Asahina, M.D., Ph.D., Professor, Department of Liver Disease Control, Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. E-mail: asahina.gast@tmd.ac.jp; fax: +81-3-5803-0268.

Copyright © 2013 by the American Association for the Study of Liver Diseases.

View this article online at [wileyonlinelibrary.com](http://wileyonlinelibrary.com).

DOI 10.1002/hep.26442

Potential conflict of interest: Dr. Asahina is on the speakers' bureau of Chugai Pharma and MSD, and received research funding from Daiichi-Sankyo and Chugai Pharma. Dr. Asahina and Dr. Kakinuma belong to a donation-funded department funded by Chugai Pharma, Toray, Bristol-Myers Squibb, Daiippon-Sumitomo Pharma, and MSD.

Additional Supporting Information may be found in the online version of this article.



**Table 1. Characteristics of Patients Enrolled in the Present Study**

Factors	Value
Patients, n	1818
Sex, n (%)	
Male	833 (45.8)
Female	985 (54.2)
Age (SD), year	57.1 (12.0)
BMI (SD), kg/m <sup>2</sup>	23.1 (3.2)
Fibrosis stage, n (%)	
F1/2	1384 (76.1)
F3/4	434 (23.9)
Activity grade, n (%)	
A0/1	964 (53.0)
A2/3	854 (47.0)
%Severe steatosis (≥10%)	23.7
Albumin (SD), g/dL	4.0 (0.38)
ALT (SD), IU/L	78.3 (71.0)
γ-GTP (SD), IU/L	49.8 (50.6)
T. Bilirubin (SD), mg/dL	0.73 (0.34)
Fasting blood sugar (SD), mg/dL	113.4 (37.8)
LDL-Cholesterol (SD), mg/dL	101.6 (28.9)
T. Cholesterol (SD), mg/dL	176.2 (38.4)
AFP (SD), ng/mL	11.3 (28.3)
WBC counts (SD), /μL	4990 (1516)
Hb (SD), g/dL	14.0 (1.7)
Platelet counts (SD), x10 <sup>3</sup> /μL	164 (54)
HCV load (SD), KIU/mL	1097 (1263)
HCV genotype, n (%) <sup>*</sup>	
1a	11 (0.56)
1b	1183 (67.4)
2a	361 (20.6)
2b	180 (10.3)
Others	20 (1.1)
%Core 70 a.a. mutation <sup>†</sup>	34.2
%ISDR wild or 1 mutation <sup>‡</sup>	63.9
IFN regimen, n (%)	
IFN mono	758 (35.0)
IFN + RBV	275 (12.7)
PEG-IFN mono	307 (14.2)
PEG-IFN + RBV	758 (38.2)

Unless otherwise indicated, data are given as mean (SD).

<sup>\*</sup>HCV genotype was determined in 1755 patients.

<sup>†</sup>HCV core mutation was determined in 409 patients with genotype 1b.

<sup>‡</sup>ISDR was determined in 1264 patients with genotype 1b.

Abbreviations: BMI, body mass index; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase; LDL, low-density lipoprotein; AFP, α-fetoprotein; WBC, white blood cell; Hb, hemoglobin; HCV, hepatitis C virus; ISDR, interferon sensitivity determining region; IFN, interferon; RBV, ribavirin; PEG, pegylated.

hematological, virological, and histological data were collected. Age was determined at the time of primary liver biopsy. Patients were examined for HCC by abdominal ultrasonography, dynamic CT, and/or MRI every 3-6 months. Serum ALT and AFP levels were measured every 1-6 months. The surveillance protocols were in accordance with the standard of care in Japan. If HCC was suspected on the basis of the screening examination, additional procedures (e.g., dynamic CT, dynamic MRI, CT during hepatic arteriography, CT during arterial portography, contrast-enhanced ultrasonography, and tumor

biopsy) were used to confirm the diagnosis. HCC diagnosis was confirmed by needle biopsy, histology of surgically resected specimens, or characteristic radiological findings. To evaluate the effects of changes in serum ALT and AFP levels during IFN therapy on hepatocarcinogenesis, the average integration values of ALT and AFP in each patient were calculated before and after IFN therapy. Data obtained more than 1 year prior to HCC development were used to exclude AFP elevation caused by HCC itself.

Follow-up was between the date of primary liver biopsy and HCC development or the last medical attendance until June 2011. The mean follow-up period was 6.1 years (range, 1.0-20.8 years).

**Statistical Analyses.** Categorical data were compared by the chi-square test or Fisher's exact test. Distributions of continuous variables were analyzed with Student *t* test for two groups. All tests of significance were two-tailed and *P* < 0.05 was considered statistically significant. The cumulative incidence curve was determined by the Kaplan-Meier method, and differences among groups were assessed using the log-rank test. Factors associated with HCC risk were determined by the Cox proportional hazard model. As covariates in the multivariate stepwise Cox model, age, sex, stage of liver fibrosis, grade of histological activity, presence of hepatic steatosis, serum albumin levels, γ-glutamyl transpeptidase (γ-GTP) level, fasting blood sugar levels, platelet counts, pre-IFN ALT levels, pre-IFN AFP levels, post-IFN ALT levels, post-IFN AFP levels, and virological response were included. HCC development was the dependent variable. Time zero was defined as the time of primary liver biopsy. The proportional assumption was supported by log[-log(survival)] versus log(time) plots that showed parallel lines. Statistical analyses were performed using the Statistical Package for the Social Sciences software v. 18.0 (SPSS, Chicago, IL).

## Results

### *Patient Characteristics and Factors Associated With Risk of HCC.*

Table 1 shows patient characteristics at the time of enrollment. During follow-up, HCC developed in 179 patients. The cumulative incidence of HCC for 5 and 10 years was 6.5% and 15.0%, respectively. The final virological response to IFN therapy was determined in all patients. The overall rate of SVRs was 50.2% (913/1818). The cumulative incidence in SVRs was 2.3% and 5.5%, respectively, which was significantly lower than that in non-SVRs (6.9% and 21.9%, respectively; log-rank test, *P* < 0.0001).

Univariate analysis demonstrated factors that increase the risk for HCC development (Table 2). According to

multivariate stepwise Cox analysis, older age, male gender, advanced fibrosis, severe steatosis, lower serum albumin levels, non-SVR, and higher post-IFN treatment ALT and AFP levels, but not pre-IFN treatment ALT and AFP levels, were identified as independent factors that were significantly associated with HCC development (Table 2).

**Association of Post-IFN Treatment ALT and AFP Levels With HCC Development in SVRs and Non-SVRs.** Because our multivariate analysis identified post-IFN treatment ALT and AFP levels as independent factors associated with HCC risk, we determined the cutoff values of these factors for predicting the development of HCC by receiver operator characteristics (ROC) analysis. The area under the ROC curve for post-IFN treatment ALT and AFP levels were higher than that for pre-IFN treatment ALT and AFP levels, suggesting that quantification of post-IFN treatment ALT and AFP levels rather than pre-IFN treatment levels of these values is useful for predicting HCC (Fig. 1A). From this ROC analysis, ALT <40 IU/L and AFP <6.0 ng/mL were identified as cutoff values. Negative predictive values were extremely high at 0.960 in each value, suggesting patients with ALT and/or AFP levels below these cutoff values are at a lower risk for HCC.

As shown in Fig. 1B, the hazard ratio determined by Cox proportional hazard analysis after adjustment for age, sex, stage of liver fibrosis, degree of liver steatosis, serum albumin levels, and virological response to therapy demonstrated that the hazard ratio for HCC was dependent on post-IFN treatment ALT and AFP levels. These hazard ratios increased predominantly when post-IFN treatment ALT and AFP levels were more than the cutoff values.

As shown in Fig. 2, the cumulative incidence of HCC was closely related to post-IFN treatment ALT and AST levels and was significantly lower in patients whose post-IFN treatment ALT and AFP levels was suppressed to <40 IU/L and 6.0 ng/mL, respectively. This suppressive effect was also notable in non-SVRs (Fig. 2C,D). Moreover, the cumulative incidence of HCC was significantly higher even in SVRs whose post-IFN treatment ALT and AFP levels were not <40 IU/L and 10 ng/mL, respectively (Fig. 2E,F).

**Changes in ALT and AFP Levels With IFN Therapy and HCC Development.** In the entire cohort, the mean ALT and AFP levels significantly decreased after IFN therapy (ALT = 78.4 to 36.6 IU/L, 95% confidence interval [CI] = 38.6-45.0,  $P < 0.0001$ ; AFP = 11.3 to 6.9 ng/mL, 95% CI = 3.25-5.69,  $P < 0.0001$ ; paired Student  $t$  test), and this significant

**Table 2. Factors Associated With Hepatocellular Carcinoma**

Risk Factor	Hazard Ratio (95% CI)	P Value
<b>Univariate analysis</b>		
Age (by every 10 year)	1.82 (1.52-2.20)	<0.0001
Sex		
Female	1	
Male	1.61 (1.20-2.17)	<0.0001
Fibrosis stage		
F1/F2	1	
F3/F4	4.90 (3.64-6.61)	<0.0001
Activity grade		
A0/A1	1	
A2/A3	3.38 (2.41-4.74)	<0.0001
Degree of steatosis		
<10%	1	
≥10%	3.84 (2.62-5.63)	<0.0001
Albumin (by every 1 g/dL)	0.18 (0.22-0.25)	<0.0001
Pre-ALT (by every 40 IU/L)	1.04 (0.96-1.08)	0.525
Post-ALT (by every 40 IU/L)	1.68 (1.55-1.81)	<0.0001
γ-GTP (by every 40 IU/L)	1.17 (1.08-1.27)	<0.0001
Fasting blood sugar (by every 100 mg/dL)	1.82 (1.35-2.45)	<0.0001
Pre-AFP (by every 10 ng/mL)	1.07 (1.05-1.09)	<0.0001
Post-AFP (by every 10 ng/mL)	1.08 (1.06-1.12)	<0.0001
Platelet counts (by every 10 <sup>4</sup> /μL)	0.88 (0.85-0.90)	<0.0001
Genotype		
Non-1	1	
1	2.27 (1.51-3.45)	<0.0001
Core 70 mutation		
Wild	1	
Mutant	2.79 (1.19-6.53)	0.018
ISDR		
More than 1 mutation	1	
Wild or 1 mutation	1.27 (0.87-1.85)	0.216
Virological response		
SVR	1	
Non-SVR	3.66 (2.51-5.35)	<0.0001
<b>Multivariate analysis</b>		
Age (by every 10 year)	2.18 (1.71-2.81)	<0.0001
Sex		
Female	1	
Male	2.66 (1.86-3.80)	<0.0001
Fibrosis stage		
F1/F2	1	
F3/F4	2.27 (1.58-3.27)	<0.0001
Degree of steatosis		
<10%	1	
≥10%	2.29 (1.49-3.50)	<0.0001
Albumin (by every 1 g/dL)	0.35 (0.23-0.55)	<0.0001
Post-ALT (by every 40 IU/L)	1.81 (1.55-2.12)	<0.0001
Post-AFP (by every 10 ng/mL)	1.06 (1.02-1.10)	0.007
Virological response		
SVR	1	
Non-SVR	1.58 (1.01-2.48)	0.044

Hazard ratios for development of hepatocellular carcinoma were calculated by the Cox proportional hazards analysis. ALT, alanine aminotransferase; γ-GTP, gamma-glutamyl transpeptidase; AFP, alpha-fetoprotein; ISDR, interferon sensitivity determining region; SVR, sustained virological responder. As covariates in the multivariate stepwise Cox model, age, sex, stage of liver fibrosis, grade of histological activity, presence of hepatic steatosis, serum albumin levels, γ-GTP level, fasting blood sugar levels, platelet counts, pre-IFN ALT levels, pre-IFN AFP levels, post-IFN ALT levels, post-IFN AFP levels, and virological response were included.

decrease was found not only in SVRs, but also non-SVRs (Fig. 3A). Because post-IFN treatment ALT and AFP levels rather than pre-IFN treatment levels were




Fig. 1. Predictive values for ALT and AFP, and hazard ratios (HRs) according to post-IFN treatment ALT and AFP levels. (A) ROC curve for prediction of HCC. Area under the ROC curve, 95% CI, cutoff value, sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) are shown in the bottom of the figure. (B) Spline curves of HR (solid line) and 95% CI (dotted line) for HCC development according to post-IFN treatment ALT and AFP levels. Curves were fitted using polynomial regression.

significantly associated with the development of HCC in non-SVRs, we determined the effects of changes in ALT and AFP levels by IFN therapy on hepatocarcinogenesis. Even in non-SVRs with equal or higher pre-IFN treatment ALT or AFP levels than the cutoff values, the cumulative incidence of HCC was significantly suppressed in patients whose post-IFN treatment ALT or AFP level was reduced to less than the cutoff values (Fig. 3B). In contrast, persistence of post-IFN treatment ALT or AFP levels to more than the cutoff values after IFN therapy was associated with a significantly higher incidence of HCC (Fig. 3B).

**Relation Between AFP and ALT or Histological Findings.** Univariate analysis using logistic regression determined factors that were associated with post-IFN treatment ALT or AFP levels (Supporting Table). Although many clinical factors were associated with post-

IFN ALT and/or AFP levels, post-IFN ALT and AFP levels were not correlated with each other ( $r^2 = 0.050$ ). Therefore, the cumulative incidence of HCC was significantly higher in patients with higher post-IFN treatment AFP levels, even when patients were stratified by post-IFN treatment ALT levels (Fig. 4A,B).

As shown in Fig. 4C-F, the cumulative incidence of HCC development was significantly lower in patients whose post-IFN treatment AFP level was  $<6.0$  ng/mL in all subgroups stratified by stage of fibrosis and grade of activity. Therefore, reduction in post-IFN treatment AFP levels reduces HCC risk even in patients with advanced fibrosis. Although pre-IFN treatment AFP levels correlated with the advance of histological fibrosis and grade of activity, such correlations became less significant with post-IFN treatment AFP levels (data not shown).

**Platelet Counts and Aspartate Aminotransferase-to-Platelet Ratio Index (APRI) in Patients Without Advanced Fibrosis.** Because a substantial amount of HCC cases developed in the patients without histologically advanced fibrosis (Fig. 4C), we characterized these individuals using platelet counts and APRI,<sup>25</sup> which are the readily available surrogate markers for liver fibrosis. We first determined the cutoff values of platelet counts and APRI for predicting HCC development by ROC analyses. Accordingly, platelet counts  $<150 \times 10^3/\mu\text{L}$  and APRI  $>0.96$  were identified as cutoff values, and the areas under the ROC curve for platelet counts and APRI were 0.715 (95% CI: 0.675–0.755) and 0.740 (95% CI: 0.701–0.779), respectively (Supporting Figure). Even in individuals without advanced fibrosis (F1 and F2 patients), the proportion of patients with platelet counts  $<150 \times 10^3/\mu\text{L}$  or APRI  $>0.96$  was significantly higher in patients with HCC than in those without HCC (platelet counts, 53.0% [35/66] versus 31.3% [387/1238],  $P = 0.0002$ ; APRI, 53.0% [35/66] versus 26.4% [325/1229],  $P < 0.0001$ ). Moreover, the cumulative incidence of HCC development was significantly higher in patients with platelet counts  $<150 \times 10^3/\mu\text{L}$  or APRI  $>0.96$  in the subgroups without advanced fibrosis (Supporting Figure). Therefore, patients with low platelet counts or high APRI still have a substantial risk for HCC development even though they were diagnosed with mild fibrosis by liver biopsy.

**Hepatic Steatosis and Post-IFN ALT and AFP Levels in SVRs.** To characterize SVRs without ALT and AFP normalization after IFN therapy, we evaluated the percentage of severe hepatic steatosis in these patients. Accordingly, the percentages of severe hepatic steatosis were significantly higher in SVRs without ALT and AFP normalization than in those with normal




Fig. 2. Cumulative incidence of HCC according to post-IFN treatment ALT and AFP levels. (A) Entire cohort stratified by post-IFN treatment ALT levels (log-rank test:  $P < 0.0001$ ). (B) Entire cohort stratified by post-IFN treatment AFP levels (log-rank test:  $P < 0.0001$ ). (C) Non-SVRs stratified by post-IFN treatment ALT levels (log-rank test:  $P < 0.0001$ ). (D) Non-SVRs stratified by post-IFN treatment AFP levels (log-rank test:  $P < 0.0001$ ). (E) SVRs stratified by post-IFN treatment ALT levels (log-rank test:  $P < 0.0001$ ). (F) SVRs stratified by post-IFN treatment AFP levels (log-rank test:  $P < 0.0001$ ). The number of HCC events and patients at risk at each timepoint are shown below the graphs.

ALT and AFP (ALT, 37.9% [36/95] versus 13.8% [77/557],  $P < 0.0001$ ; AFP, 31.6% [31/98] versus 14.8% [82/554],  $P < 0.0001$ ). Therefore, it is likely that

presence of hepatic steatosis is associated with ALT and/or AFP elevation, and it is one of the risks for HCC development even after achieving SVR.




Fig. 3. Changes in pre- and post-IFN treatment ALT and AFP levels, and their effects on HCC development. (A) Mean serum pre- (open columns) and post-IFN treatment (solid columns) ALT and AFP levels in SVRs and non-SVRs. Error bars indicate the standard error. \*Paired Student *t* test. †Unpaired Student *t* test. (B) Cumulative incidence of HCC stratified by changes in pre- and post-IFN treatment ALT and AFP levels (log-rank test:  $P < 0.0001$ ). ALT  $< 40 \rightarrow$  unchanged, patients with ALT  $< 40$  IU/L before IFN therapy unchanged after IFN therapy; ALT  $\geq 40 \rightarrow$  decreased, patients with ALT  $\geq 40$  IU/L before IFN therapy decreased to ALT  $< 40$  IU/L after IFN therapy; ALT  $\geq 40 \rightarrow$  unchanged, patients with ALT  $\geq 40$  IU/L before IFN therapy unchanged at ALT not  $< 40$  IU/L after IFN therapy. AFP  $< 6.0 \rightarrow$  unchanged, patients with AFP  $< 6.0$  ng/mL before IFN therapy unchanged at AFP  $< 6.0$  ng/mL after IFN therapy; AFP  $\geq 6.0 \rightarrow$  decreased, patients with AFP  $\geq 6.0$  ng/mL before IFN therapy decreased to AFP  $< 6.0$  ng/mL after IFN therapy; AFP  $\geq 6.0 \rightarrow$  unchanged, patients with AFP  $\geq 6.0$  ng/mL before IFN therapy unchanged at AFP  $\geq 6.0$  ng/mL after IFN therapy.

## Discussion

This large-scale, long-term cohort study establishes important findings, which demonstrate a strict association between hepatocarcinogenesis and post-IFN

treatment ALT and AFP levels in patients with CHC. This association was notable in both SVR and non-SVR subgroups, and suppression of these values by IFN therapy reduced the hepatocarcinogenesis risk despite failure of HCV eradication. These data, which




Fig. 4. Relationship between AFP and ALT or histological findings. (A) The cumulative incidence of HCC stratified by post-IFN treatment AFP levels in subgroups according to the post-IFN treatment ALT (log-rank test:  $P < 0.0001$  in both subgroups). (B) Cumulative incidence of HCC stratified by post-IFN treatment AFP levels in subgroups according to the histological stage of fibrosis (log-rank test:  $P < 0.0001$  in both subgroups). (C) Cumulative incidence of HCC stratified by post-IFN treatment levels of AFP in subgroups according to the histological grade of activity (log-rank test:  $P < 0.0001$  in both subgroups).

demonstrate the efficacy of IFN against HCC development associated with suppression of AFP, have clinically important implications for physicians.

Although there have been reports on the association between baseline pretreatment AFP levels and HCC risk,<sup>26-35</sup> little is known regarding the effects of IFN therapy on change in post-IFN treatment AFP and its

relation to HCC risk.<sup>36</sup> Although a previous report demonstrated that a decrease in AFP levels in patients receiving IFN therapy reduced the incidence of HCC,<sup>37</sup> this study was performed in a small number of patients ( $n = 382$ ), and cutoff values, relation to ALT, or histological findings were not determined. Our study, performed in a large well-characterized

cohort, had a greater advantage in that it allowed determination of cutoff values for post-IFN treatment ALT and AFP levels useful for predicting HCC development. Although a higher cutoff value of 20 ng/mL was used to determine the incidence of HCC in the previous study,<sup>36</sup> we propose a lower value for negatively predicting HCC. From our results, those with AFP levels  $\geq 6.0$  ng/mL have a substantial HCC risk, even if it is  $< 20$  ng/mL. Therefore, post-IFN treatment AFP levels should be  $< 6.0$  ng/mL to suppress HCC risk in patients with CHC.

It should be noted that AFP produced by HCC itself was carefully excluded in our study. Serum AFP elevation is frequently observed in patients with advanced CHC in the absence of HCC.<sup>19-23</sup> Although the precise mechanisms accounting for this observation are unknown, Hu et al.<sup>38</sup> found a correlation between AFP and measures of liver disease activity, suggesting that AFP production is enhanced in the presence of necroinflammatory injury of the liver. However, in our study post-IFN treatment ALT and AFP levels were not correlated, and the cumulative incidence of HCC was significantly higher in patients with higher post-IFN treatment AFP levels, even when patients were stratified by post-IFN treatment ALT levels. Moreover, multivariate analysis confirmed that AFP and ALT are independently associated with HCC risk. Therefore, observed elevation in AFP levels in patients with subsequent HCC development is not necessarily caused by necroinflammation of the liver. Alternatively, increased AFP levels have been reported during liver regeneration following hepatic resection and during recovery from massive hepatic necrosis,<sup>39-41</sup> suggesting that elevated AFP levels are a surrogate for proliferative activity of liver cells, which may cause hepatocarcinogenesis in patients with CHC.

Other possible reasons accounting for HCC risk related to AFP are the close association between AFP levels and the stage of liver fibrosis, which is consistent with a previous report.<sup>35</sup> However, we further clarified the fact that correlation between post-IFN treatment AFP levels and liver fibrosis was less notable in patients without subsequent development of HCC (data not shown). Cumulative incidence of HCC was significantly higher in patients with higher post-IFN treatment AFP levels at each stage when patients were stratified by the histological stage of fibrosis (Fig. 4). Therefore, post-IFN treatment AFP is not just a surrogate marker for liver fibrosis, and elevation of post-IFN treatment AFP as a potential risk for hepatocarcinogenesis is not only the result of advanced liver fibrosis. Conversely, suppression of post-IFN treatment

AFP levels may reduce HCC risk even in patients with advanced fibrosis.

This study has a few limitations, the first being the heterogeneity of our cohort, which included various treatment regimens with different treatment responses. However, we obtained similar results in a more uniform subgroup of HCV genotype 1b patients treated with PEG-IFN $\alpha$ /RBV (data not shown). The second limitation is the ethnic homogeneity of the Japanese population. Because the baseline incidence of HCC development differs among population groups, longer-term longitudinal studies in larger cohorts with various population subgroups are required to verify the generality of our results.

With the development of potent direct-acting antiviral agents combinations, IFN-free therapy is likely to be approved in the near future. This raises the question of whether posttreatment ALT and/or AFP levels will remain a significant predictor of HCC risk. Moreover, it is uncertain whether the suppressive effect of viral eradication by IFN-free regimens on hepatocarcinogenesis will be identical to that obtained by IFN-based regimens. Therefore, it is extremely interesting to prove these issues in future studies.

In conclusion, post-IFN treatment ALT and AFP levels are strictly associated with hepatocarcinogenesis risk in patients with CHC. Measurement of these values is useful for predicting future HCC risk in IFN-treated patients. Suppression of these values after IFN therapy reduces HCC risk even in patients without HCV eradication, while SVRs with increased ALT and/or AFP levels are at risk for HCC development. The present results have potentially important clinical implications for physicians and may influence their decisions regarding treatment strategy and HCC surveillance for individual patients.

## References

1. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. *Semin Liver Dis* 1995;15:64-69.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet* 2003;362:1907-1917.
3. Parkin DM. Global cancer statistics in the year 2000. *Lancet Oncol* 2001;2:533-543.
4. Kiyosawa K, Sodeyama T, Tanaka E, Gigo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. *HEPATOLOGY* 1990;12:671-675.
5. Asahina Y, Tsuchiya K, Tamaki T, Hirayama I, Tanaka T, Sato M, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. *HEPATOLOGY* 2010;52:518-527.
6. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of IFN therapy and hepatocellular carcinoma in patients with chronic hepatitis C. *Ann Intern Med* 1998;129:94-99.
7. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of IFN therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643

- patients using statistical bias correction with proportional hazard analysis. *HEPATOLOGY* 1999;29:1124-1130.
8. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. IFN therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. *Ann Intern Med* 1999;131:174-181.
  9. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al. SVR to IFN-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. *HEPATOLOGY* 2007;45:579-587.
  10. Lazarevich NL. Molecular mechanisms of alpha-fetoprotein gene expression. *Biochemistry (Mosc)* 2000;65:117-133.
  11. Ball D, Rose E, Alpert E. Alpha-fetoprotein levels in normal adults. *Am J Med Sci* 1992;303:157-159.
  12. Matsui H, Rimal N, Kamakura K, Uesugi S, Yamamoto H, Ikeda S, et al. Serum alpha-fetoprotein levels in healthy Japanese adults. *Acta Med Okayama* 1998;52:149-154.
  13. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. *Semin Liver Dis* 2005;25:143-154.
  14. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. *J Hepatol* 2001;34:570-575.
  15. Cedrone A, Covino M, Caturelli E, Pompili M, Lorenzelli G, Villani MR, et al. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 Western patients. *Hepatogastroenterology* 2000;47:1654-1658.
  16. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. *HEPATOLOGY* 2002;36:S84-S92.
  17. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost utility analysis. *Am J Gastroenterol* 2003;98:679-690.
  18. Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. *HEPATOLOGY* 2002;36:410-417.
  19. Di Bisceglie AM, Hoofnagle JH. Elevations in serum alphafetoprotein levels in patients with chronic hepatitis B. *Cancer* 1989;64:2117-2120.
  20. Liaw YF, Tai DI, Chen TJ, Chu CM, Huang MJ. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. *Liver* 1986;6:133-137.
  21. Bayati N, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. *Am J Gastroenterol* 1998;93:2452-2456.
  22. Goldstein NS, Blue DE, Hankin R, Hunter S, Bayati N, Silverman AL, et al. Serum alpha-fetoprotein levels in patients with chronic hepatitis C. Relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. *Am J Clin Pathol* 1999;111:811-816.
  23. Chu CW, Hwang SJ, Luo JC, Lai CR, Tsay SH, Li CP, et al. Clinical, virologic, and pathologic significance of elevated serum alphafetoprotein levels in patients with chronic hepatitis C. *J Clin Gastroenterol* 2001;32:240-244.
  24. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. *HEPATOLOGY* 1994;19:1513-1520.
  25. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *HEPATOLOGY* 2003;38:518-526.
  26. Rodriguez-Diaz JL, Rosas-Camargo V, Vega-Vega O, Morales-Espinosa D, Mendez-Reguera A, Martinez-Tlahuel JL, et al. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study. *Clin Oncol* 2007;19:197-203.
  27. Bruix J, Sherman M. Management of hepatocellular carcinoma. *HEPATOLOGY* 2005;42:1208-1236.
  28. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. *N Engl J Med* 1991;325:675-680.
  29. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. *N Engl J Med* 1993;328:1797-1801.
  30. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. *HEPATOLOGY* 1994;19:61-66.
  31. Ganne-Carrie N, Chastang C, Chapel F, Munz C, Pateron D, Sibony M, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. *HEPATOLOGY* 1996;23:1112-1118.
  32. Sangiovanni A, Colombo E, Radaelli F, Bortoli A, Bovo G, Casiraghi MA, et al. Hepatocyte proliferation and risk of hepatocellular carcinoma in cirrhotic patients. *Am J Gastroenterol* 2001;96:1575-1580.
  33. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Someya T, Hosaka T, et al. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. *J Hepatol* 2006;44:1089-1097.
  34. Bruce MG, Bruden D, McMahon BJ, Christensen C, Homan C, Sullivan D, et al. Clinical significance of elevated alpha-fetoprotein in Alaskan Native patients with chronic hepatitis C. *J Viral Hepat* 2008;15:179-187.
  35. Tateyama M, Yatsuhashi H, Taura N, Motoyoshi Y, Nagaoka S, Yanagi K, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. *J Gastroenterol* 2010;46:92-100.
  36. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. *J Hepatol* 2005;43:434-441.
  37. Osaki Y, Ueda Y, Marusawa H, Nakajima J, Kimura T, Kita R, et al. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. *J Gastroenterol* 2012;47:444-451.
  38. Hu K-Q, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. *Am J Gastroenterol* 2004;99:860-865.
  39. Watanabe A, Shiota T, Hayashi S, Nagashima H. Serum alphafetoprotein in fulminant hepatitis and hepatic regeneration following partial hepatectomy. *Biochem Med* 1984;32:132-137.
  40. Yang SS, Cheng KS, Lai YC, Wu CH, Chen TK, Lee CL, Chen DS. Decreasing serum alpha-fetoprotein levels in predicting poor prognosis of acute hepatic failure in patients with chronic hepatitis B. *J Gastroenterol* 2002;37:626-632.
  41. Horn KD, Wax P, Schneider SM, Martin TG, Nine JS, Moraca MA, et al. Biomarkers of liver regeneration allow early prediction of hepatic recovery after acute necrosis. *Am J Clin Pathol* 1999;112:351-357.



## Inhibition of hepatocellular carcinoma by PegIFN $\alpha$ -2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study

Namiki Izumi · Yasuhiro Asahina · Masayuki Kurosaki · Gotaro Yamada · Tsutomu Kawai · Eiji Kajiwara · Yukishige Okamura · Takayuki Takeuchi · Osamu Yokosuka · Kazuya Kariyama · Joji Toyoda · Mie Inao · Eiji Tanaka · Hisataka Moriwaki · Hiroshi Adachi · Shinji Katsushima · Masatoshi Kudo · Kouichi Takaguchi · Yoichi Hiasa · Kazuaki Chayama · Hiroshi Yatsunami · Makoto Oketani · Hiromitsu Kumada

Received: 23 April 2012 / Accepted: 25 June 2012 / Published online: 9 August 2012  
© The Author(s) 2012. This article is published with open access at Springerlink.com

### Abstract

**Background** We investigated whether the administration of maintenance doses of interferon prevented hepatocellular carcinoma (HCC) in patients with chronic hepatitis C. **Methods** Study 1: A multicenter, retrospective, cooperative study was carried out to determine whether long-term administration of low-dose peginterferon alpha-2a

(PegIFN $\alpha$ -2a) prevented HCC development in patients with chronic hepatitis C. In total, 594 chronic hepatitis C patients without a history of HCC were enrolled and treated with 90  $\mu$ g PegIFN $\alpha$ -2a administered weekly or bi-weekly for at least 1 year. Study 2: HCC developed in 16 of 99 additional patients without PegIFN $\alpha$ -2a treatment during 3.8 years of observation. A propensity-matched control study was then carried out to compare the incidence of

N. Izumi (✉) · Y. Asahina · M. Kurosaki  
Department of Gastroenterology and Hepatology,  
Musashino Red-Cross Hospital, Musashino, Japan  
e-mail: nizumi@musashino.jrc.or.jp

G. Yamada  
Department of Internal Medicine, Kawasaki Hospital  
of Kawasaki Medical University, Okayama, Japan

T. Kawai  
Department of Gastroenterology, Kanbara General Hospital,  
Fuji, Japan

E. Kajiwara  
Department of Gastroenterology, Shinnittetsu Yahata Memorial  
Hospital, Kitakyushu, Japan

Y. Okamura  
Department of Gastroenterology, Sano Kousei Hospital,  
Kitakyushu, Japan

T. Takeuchi  
Department of Gastroenterology, Notogawa Hospital,  
Higashiomi, Japan

O. Yokosuka  
Department of Gastroenterology and Hepatology, Chiba  
University, Chiba, Japan

K. Kariyama  
Department of Hepatology, Okayama Citizens' Hospital,  
Okayama, Japan

J. Toyoda  
Department of Gastroenterology and Hepatology,  
Sapporo Kousei Hospital, Sapporo, Japan

M. Inao  
Department of Gastroenterology and Hepatology,  
Saitama Medical University, Moroyama, Japan

E. Tanaka  
Second Department of Internal Medicine,  
Shinshu University, Matsumoto, Japan

H. Moriwaki  
Department of Gastroenterology and Hepatology,  
Gifu University, Gifu, Japan

H. Adachi  
Department of Hepatology, Tonami General Hospital,  
Tonami, Japan

S. Katsushima  
Department of Gastroenterology, Kyoto Medical Center,  
Kyoto, Japan

M. Kudo  
Department of Gastroenterology and Hepatology,  
Kinki University, Higashiosaka, Japan

K. Takaguchi  
Department of Gastroenterology, Kagawa Central Hospital,  
Takamatsu, Japan

HCC between the 59 patients who received low-dose PegIFN $\alpha$ -2a (PegIFN $\alpha$ -2a group) and 59 patients who did not receive PegIFN $\alpha$ -2a treatment (control group), matched for sex, age, platelet count, and total bilirubin levels.

**Results** Study 1: HCC developed in 49 patients. The risk of HCC was lower in patients with undetectable hepatitis C virus RNA,  $\leq 40$  IU/L alanine aminotransferase (ALT), or  $\leq 10$  ng/L alpha-fetoprotein (AFP) 24 weeks after the start of therapy. Study 2: The incidence of HCC was significantly lower in the PegIFN $\alpha$ -2a group than in the control group.

**Conclusions** Low-dose and long-term maintenance administration of PegIFN $\alpha$ -2a decreased the incidence of HCC in patients with normalized ALT and AFP levels at 24 weeks compared with patients without normal ALT and AFP levels.

**Keywords** Chronic hepatitis C · Hepatocellular carcinoma · Peginterferon

## Introduction

Hepatocellular carcinoma (HCC), the sixth most common cancer worldwide, often develops because of long-term hepatitis B or C virus infection [1, 2]. In particular, chronic hepatitis C and hepatic cirrhosis increase the risk of HCC; the annual incidence of tumor development in such patients may be as high as 2–4 % [3–5]. The incidence of HCC decreases in patients who achieve a sustained virological response (SVR) to interferon (IFN) treatment, although the incidence remains high in non-SVR patients [6–9]. A detailed analysis of HCC development revealed that chronic hepatitis C patients aged 65 years or more, especially those with advanced fibrosis of the liver, were at an increased risk of developing HCC [10]. For patients

65 years or older with advanced liver fibrosis, the dose of ribavirin is often reduced or the agent is discontinued, resulting in lower SVR rates in those with discontinuation of ribavirin. Establishing an effective treatment strategy for preventing the development of HCC is important for these high-risk patients.

Factors related to the development of HCC have been analyzed in patients who did not achieve an SVR even after IFN treatment; advanced fibrosis of the liver and high levels of serum alanine aminotransferase (ALT), and alpha-fetoprotein (AFP) are risk factors for HCC development [11, 12]. A randomized controlled trial was conducted in Western countries to determine whether combined peginterferon and ribavirin treatment with weekly administration of 90  $\mu$ g peginterferon alpha-2a (PegIFN $\alpha$ -2a) could prevent HCC in non-responders. A 3.5-year follow up showed that administration of a maintenance dose of PegIFN $\alpha$ -2a did not reduce tumor incidence in these patients [13]. However, after 8.5 years of observation, the incidence of HCC was decreased among those in the PegIFN $\alpha$ -2a group with cirrhosis [14]. Meanwhile, Bruix et al. [15] reported that maintenance therapy with PegIFN $\alpha$ -2b did not prevent HCC in chronic hepatitis C patients with cirrhosis. In Japan, long-term low-dose administration of natural IFN has been reported to decrease the incidence of HCC [16]. In light of these conflicting results, investigations should be carried out in a large number of patients with chronic hepatitis C to resolve the question of whether IFN treatment prevents the development of HCC.

We carried out a multicenter retrospective cooperative study of patients with chronic hepatitis C to determine whether those treated with 90  $\mu$ g PegIFN $\alpha$ -2a without ribavirin had a reduced incidence of HCC compared with those not treated with IFN.

## Patients and methods

**Study 1: analysis of risk factors for HCC in patients treated with long-term low-dose-PegIFN $\alpha$ -2a**

In total, at 21 hepatitis centers throughout Japan, 743 patients with hepatitis C who had received 90  $\mu$ g of PegIFN $\alpha$ -2a therapy weekly or bi-weekly for 1 year or more without having received the full dose (180  $\mu$ g) since December 2003 were examined retrospectively for the development of HCC. The end of enrollment in this study was the end of December 2008 and the end of follow up was the end of December 2010. Patients with a history of HCC before the start of therapy and those with a therapy period of less than 48 weeks were excluded, leaving 594 patients who had undergone long-term administration of PegIFN $\alpha$ -2a for analysis. At the 21 centers involved in this

Y. Hiasa  
Department of Gastroenterology and Hepatology,  
Ehime University, Matsuyama, Japan


K. Chayama  
Department of Gastroenterology and Hepatology,  
Hiroshima University, Hiroshima, Japan

H. Yatsunami  
Department of Gastroenterology and Hepatology,  
Nagasaki Medical Center, Nagasaki, Japan

M. Oketani  
Department of Gastroenterology and Hepatology,  
Kagoshima University, Kagoshima, Japan

H. Kumada  
Department of Hepatology, Toranomon Hospital, Tokyo, Japan

**Fig. 1** Flow diagram of the patients' enrollment in the study. *Peg-IFN $\alpha$*  pegylated interferon  $\alpha$ , *SVR* sustained viral response, *HCC* hepatocellular carcinoma, *w* week



study, 4,753 patients with chronic hepatitis C had been treated; Peg-IFN and ribavirin combination treatment had been administered to 3,877 patients, 743 patients had received Peg-IFN alone, and 133 patients had not agreed to receive IFN (a flow diagram of the enrollment of patients in this study is shown in Fig. 1). In the patients with Peg-IFN and ribavirin combination treatment, the SVR rate was 43.8 %; SVR was not achieved in 2,179 patients, and in 776 of these patients, the combination therapy was discontinued owing to adverse events or the patient's choice. Patients who failed to achieve an SVR were not included in this study, because the incidence of HCC is known to be reduced even in non-responders to IFN [17].

The backgrounds of the 594 patients studied are shown in Table 1. Findings from the liver biopsies of the patients were classified according to international standards [18]. Long-term PegIFN $\alpha$ -2a treatment is approved by the Japanese Medical Insurance system. Written informed consent was obtained from all patients prior to participation in this study. The study design was approved by the regional ethics committees of the 21 centers involved in this study, including the Musashino Red Cross Hospital, in accordance with the Helsinki Declaration. The 743 patients treated with PegIFN $\alpha$ -2a alone were not indicated for Peg-IFN $\alpha$  and ribavirin combination therapy because of anemia or heart disease. The 133 patients who did not agree to receive IFN served as the control group (see Fig. 1). A large proportion of the 594 study patients had advanced fibrosis of the liver and active inflammation. A dose of 90  $\mu$ g PegIFN $\alpha$ -2a was administered to 512 and 82 patients weekly and biweekly, respectively, according to the patients' wishes. There were no significant differences between the weekly and biweekly groups in the patients' background data (data not shown).

The median duration of follow up in the PegIFN $\alpha$ -2a group was 1,273 days (range 228–2,768 days) and HCC was observed in 49 of the 594 patients (Table 1). Pre-treatment and on-treatment factors associated with the development of HCC were analyzed by Student's *t*-test, the

**Table 1** Background data of patients treated with PegIFN $\alpha$ -2a ( $n = 594$ )

	$n = 594$
Age (years)	61.7 $\pm$ 11.7
Sex (male/female)	258/336
BMI	23.2 $\pm$ 3.3
Genotype (1/2)	443/151
Diagnosis (ASC/CH/LC)	4/460/130
History of excess alcohol consumption ( $\geq 60$ g/day; yes/no)	118/376
Fibrosis (F0, 1, 2/F3, 4)	443/151
Inflammatory activity (A0, 1/A2, 3)	469/125
Diabetes mellitus (no/yes)	499/95
LDL cholesterol (mg/dL)	94.2 $\pm$ 31.1
Fasting blood sugar (mg/dL)	106.3 $\pm$ 28.5
White blood cell count (/mm <sup>3</sup> )	4,360 $\pm$ 1,470
Red blood cell count ( $\times 10^6/\mu$ L)	423.8 $\pm$ 56.4
Hemoglobin (g/dL)	13.3 $\pm$ 1.8
Platelet count ( $\times 10^3/\mu$ L)	137 $\pm$ 56
Albumin (g/dL)	4.0 $\pm$ 0.5
Total bilirubin (mg/dL)	0.8 $\pm$ 0.6
AST (IU/L)	65.8 $\pm$ 47.8
ALT (IU/L)	72.1 $\pm$ 68.0
Gamma-GTP (IU/L)	55.2 $\pm$ 51.3
Esophageal varices (no/yes)	344/31
Alpha fetoprotein (ng/L)	6.9 (4.2–13.8)
Once weekly or biweekly PegIFN $\alpha$ -2a	512:82
Baseline HCV RNA (KIU/mL)	1,024 (73–2,130)
Development of HCC (no/yes)	545/49

*PegIFN* pegylated interferon, *BMI* body mass index, *ASC* asymptomatic carrier, *CH* chronic hepatitis, *LC* liver cirrhosis, *LDL* low-density lipoprotein, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *GTP* guanosine triphosphate, *HCV* hepatitis C virus, *HCC* hepatocellular carcinoma

Values are means  $\pm$  SD, with ranges in parentheses

Mann–Whitney *U*-test, and the  $\chi^2$  test (Table 2). Independent factors for the development of HCC were assessed by multivariate analysis using logistic regression. The

incidence of HCC was analyzed according to the ALT, AFP, and hepatitis C virus (HCV) RNA levels 24 weeks after the start of PegIFN $\alpha$ -2a administration by using the Kaplan–Meier method. The risk of HCC was analyzed, using the Kaplan–Meier method, only in the non-responders with detectable HCV RNA during PegIFN $\alpha$ -2a administration by dividing them according to the ALT and AFP levels 24 weeks after the start of therapy. The incidence of HCC was compared between the patients with ALT levels of <41 IU/L and those with levels of  $\geq$ 41 IU/L, and between patients with serum AFP levels of <10 ng/L and those with levels of  $\geq$ 10 ng/mL at 24 weeks after starting treatment, because at most of the centers participating in the this study, the upper normal range of serum ALT is set at 40 IU/L, and the most significant difference in the incidence of HCC was observed between the PegIFN $\alpha$ -2a and control group with the cut-off serum ALT set at 41 IU/L and cutoff serum AFP set at 10 ng/mL, 24 weeks after starting treatment. The HCV RNA level was measured using the Amplicor Monitor method with a lower detection limit of 50 IU/L (Roche Diagnostics, Tokyo, Japan). A history of excess alcohol consumption was determined as >60 g alcohol per day in order to exclude alcoholic liver disease.

An asymptomatic carrier was defined as a patient with a serum ALT level within the normal range and minimal inflammation or fibrosis in the biopsied tissues of the liver. Chronic hepatitis was defined as mild-to-severe fibrosis of the liver according to liver biopsy [18]. The diagnosis of liver cirrhosis was based on the results of histological examination of the biopsied liver tissues.

**Study 2: incidence of HCC in the PegIFN $\alpha$ -2a therapy and non-administration (control) groups in comparison with propensity-matched controls**

Ninety-nine of the 133 chronic hepatitis C patients who had not received IFN were examined as controls; patients in this group received liver-protective agents such as glycyrrhizin or were untreated, and the group was observed for more than 1 year. None of the individuals in the control groups had received IFN alone or PegIFN $\alpha$  and ribavirin combination treatment. They were treated for a median of 1,395 days (range 75–6,556 days). Fifty-nine of these patients underwent liver biopsy before the treatment and were considered the control group for the propensity-matched study. For the propensity-matched study, 59 patients were selected from the PegIFN $\alpha$ -2a group according to their age, sex, platelet count, and total bilirubin levels, which had been identified as independent pretreatment risk factors for the development of HCC in Study 1. The rates of HCC were analyzed using the Kaplan–Meier method, and the risk of HCC was analyzed particularly in patients with advanced fibrosis of the liver (F3 and F4).

**Table 2** Comparison of HCC and non-HCC patients with long-term PegIFN $\alpha$ -2a administration (n = 594)

	Patients with or without development of HCC		p value
	With HCC (n = 49)	Without HCC (n = 545)	
<b>Pretreatment parameters</b>			
Age (years)	63.8 $\pm$ 1.7	61.3 $\pm$ 0.5	<0.05
Sex (male/female)	32/17	226/319	<0.01
BMI	24.0 $\pm$ 0.5	23.1 $\pm$ 0.2	n.s.
Genotype (1/2)	47/6	397/148	n.s.
History of excess alcohol consumption ( $\geq$ 60 g/day; yes/no)	11/38	107/338	n.s.
Fibrosis (F0, 1, 2/F3, 4)	25/24	418/127	<0.001
Inflammatory activity (A0, 1/A2, 3)	7/42	462/83	<0.001
Diabetes mellitus (no/yes)	38/11	461/84	n.s.
LDL cholesterol (mg/dL)	88.2 $\pm$ 9.0	94.7 $\pm$ 2.6	n.s.
White blood cell count (/mm <sup>3</sup> )	4,355 $\pm$ 210	4,360 $\pm$ 64	n.s.
Red blood cell count ( $\times 10^6/\mu$ L)	420.8 $\pm$ 8.1	424.1 $\pm$ 2.6	n.s.
Hemoglobin (g/dL)	13.6 $\pm$ 0.3	13.3 $\pm$ 0.1	n.s.
Platelet count ( $\times 10^3/\mu$ L)	106 $\pm$ 8	140 $\pm$ 2	<0.001
Albumin (g/dL)	3.8 $\pm$ 0.1	4.0 $\pm$ 0.1	<0.001
Total bilirubin (mg/dL)	1.2 $\pm$ 0.1	0.8 $\pm$ 0.1	<0.001
AST (IU/L)	78.1 $\pm$ 6.8	64.6 $\pm$ 2.1	n.s.
ALT (IU/L)	72.8 $\pm$ 9.7	72.0 $\pm$ 2.9	n.s.
Gamma-GTP (IU/L)	68.7 $\pm$ 7.5	53.9 $\pm$ 2.3	n.s.
Alpha fetoprotein (ng/L)	17.1 (4.4–36.8)	16.7 (4.1–23.1)	n.s.
Esophageal varices	29.0 % (9/31)	6.4 % (22/344)	<0.01
<b>On-treatment parameters</b>			
ALT (IU/L)	59.4 $\pm$ 5.7	44.6 $\pm$ 1.8	<0.05
Alpha fetoprotein (ng/L)	9.8 (4.6–17.4)	5.5 (3.7–11.1)	<0.01
HCV RNA level (KIU/mL)	236 (<0.5–2,210)	21 (<0.5–1,780)	<0.05

n.s. not significant

**Statistical analysis**

Categorical data were compared using the  $\chi^2$  test or Fisher’s exact test. The distributions of continuous variables were analyzed using Student’s *t*-test and the Mann–Whitney *U*-test for two groups. Multivariate analysis was